• Attach an infusion set containing a 0.20/0.22 µm filter to the IV bag. • Prime the infusion set and adjust for a flow rate of 200mL/hr for both infusion pumps and gravity infusion. Administer the infusion solution over 60 minutes. Infusion sites of care can use the following chart to calculate a 60 minute drip rate when administering via gravity infusion. 60 Minute Drip Rate for Gravity Infusion Drip factor Drops per Drops per VTBI (mL) Duration (min) (drops per minute 15 seconds milliliter) 200 60 10 gtt/mL 33 gtt/min 8 drops per 15 seconds 200 60 12 gtt/mL 40 gtt/min 10 drops per 15 seconds 200 60 15 gtt/mL 50 gtt/min 13 drops per 15 seconds 200 60 20 gtt/mL 67 gtt/min 17 drops per 15 seconds 200 60 60 gtt/mL 200 gtt/min 50 drops per 15 seconds • At the discretion of the infusion site of care medical staff, the proposed infusion rate may be reduced and the corresponding infusion time increased for infusion reactions or patient circumstances. • This product is preservative-free and therefore, the diluted infusion solution should be administered immediately. If immediate administration is not possible (and the solution has been prepared according to USP 797 guidelines), store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) or up to 7 hours at room temperature (20°C to 25°C [68°F to 77°F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration. The hold time includes preparation, solution hold, infusion and flush. Any solution which exceeds these time period requirements and/or is not compounded according to USP 797 guidelines MUST BE DISCARDED and a fresh solution MUST BE PREPARED. • After the entire infusion volume of 200mL has been administered, flush the infusion line as per infusion site of care requirements or with sufficient volume to flush residual volume from tubing to ensure patient receives entire dose. Discard unused product. • For additional information, please see Fact Sheet for Healthcare Providers. Lilly Bamlanivimab Antibody Playbook | 18 PP-BM-US-0024